

Bulletin from the annual general meeting of CombiGene AB (publ)

The following resolutions were passed at the Annual General Meeting (the "AGM") of CombiGene AB (publ) (the "Company") on 23 May 2024 in Stockholm.

Adoption of income statement and balance sheet and discharge from liability

The AGM resolved to adopt the income statement and balance sheet of the Company and the group for the financial year 2023. The AGM also resolved to discharge the members of the Board of Directors and the CEO from liability for their management of the Company's affairs during the financial year 2023.

Allocation of profit or loss

The AGM resolved, in accordance with the Board of Directors' proposal, that no dividend shall be paid for 2023 and that the results of the Company shall be carried forward.

Board of Directors and auditor

The AGM resolved, in accordance with the shareholder Orphazyme A/S' proposal, on re-election of Jonas Ekblom, Peter Nilsson, Per Lundin, Gunilla Lundmark and Malin Almgren, and on new election of Marcus Isaksson, as Board members. Jonas Ekblom was re-elected as chairman of the Board of Directors. The AGM re-elected the audit firm Mazars AB as auditor.

The AGM further resolved on remuneration to the Board of Directors in accordance with the Nomination Committee's proposal. The AGM furthermore resolved in accordance with the Nomination Committee's proposal, that remuneration to the auditor shall be paid in accordance with approved statement of costs.

Nomination Committee for the next AGM

The AGM resolved, in accordance with the Nomination Committee's proposal, on principles for the appointment of the Nomination Committee for the next AGM.

Amendment of the Articles of Association

The AGM resolved, in accordance with the Board of Directors' proposal, to amend the Articles of Association. The amendments entail that the object of the business is changed to better reflect the Company's current business, that the Board of Directors is allowed to collect proxies in accordance with Chapter 7, Section 4 of the Swedish Companies Act, and that the Board of Directors is given the opportunity to resolve before a general meeting that shareholders shall be able to exercise their voting rights by voting by mail, and that the general meeting may be held digitally.

Contacts

CombiGene AB (publ)
Peter Ekolind, CEO
Phone: +46 (0)8 35 73 55
peter.ekolind@combigene.com

www.combigene.com

CombiGene AB (publ) Agavägen 52A, SE-181 55 Lidingö, Sweden
+46-8-357355 info@combigene.com

About CombiGene

CombiGene's vision is to provide patients affected by severe diseases with the prospect of a better life through gene therapy and other forms of advanced treatments.

Our business has three focus areas: sourcing of new and promising assets, development of these assets to proof of concept under our management and expertise, and outlicensing of the assets to a strategic partner for continued development and commercialization. Revenue is achieved through milestone payments and royalties.

The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company's Certified Advisor is FNCA Sweden AB.

Please read *Ingenuous*, a newsletter from CombiGene which contains general news and information that is judged not to have a significant effect on the share price. *Ingenuous* and press releases are available at www.combigene.com